Terry Chrisomalis

Pharma/Biotech Analyst

I am a graduate of Industrial and Business Service Management. I have been investing and writing about biotechnology stocks for many years now and have extensive experience writing about the science and companies themselves. I am a contributor to more

Following: 59 Followers: 3433

Contributor's comments
Comments on contributor's content by other members

Latest Comments

Filter by Symbol:

Sarepta Tumbles On New Drug Data But Presents A Big Buying Opportunity

9 years ago

Well since (RNA) Prosensa Holdings failed there 3 trial, I was describing how analysts and few people on wall street are predicting (meaning they don't know they are just hypothesizing) that the NDA will be delayed because they think the FDA will require Sarepta to run a phase 3 trial. Now nobody knows what the FDA will want but lets say hypothetically they do want a phase 3 trial it will be a longer term play. Either way Sarepta has shown great results and boys with DMD need a safe treatment.

In this article: RNA, SRPT

Interview With RXi Pharmaceuticals Management

10 years ago

RXi is set to present at the Jefferies Health Conference Next week If they show an update on phase 2 hypertrophic scars and it's good it could propel the stock higher!